Fig. 1: Sitagliptin prevents TNFα-activated NFκB signaling pathway. | Cell Death Discovery

Fig. 1: Sitagliptin prevents TNFα-activated NFκB signaling pathway.

From: Dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin alleviates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NFκB pathway

Fig. 1

A After 24 h TNFα (20 ng/ml) or TNFα + SITA (100 μM) treatment, DPP4 activity in HepG2 cells were detected. B HepG2 cells were co-stimulated recombinant human DPP4 (hDPP4, 0.1 and 1 μg/ml) protein with sitagliptin for 24 h, after that the activity of DPP4 was determined. C Western blots and quantitative analysis of the effects of sitagliptin on the protein levels of DPP4, IKKα, p-P65S536, P65, IKBα, and p-IKBαS36 in TNFα or TNFα + SITA-treated HepG2 cells and primary mouse hepatocytes. D Western blottings and quantitative analysis of the effects of different concentrations of hDPP4 on the protein levels of DPP4, IKKα, p-P65S536, P65, IKBα, and p-IKBαS36 in HepG2 cells. The results are presented as mean ± SEM of three independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page